Evidence map›Paper›PMID 37451261›Full record

ArticleStem cell reports2023

Am80, a retinoic acid receptor agonist, activates the cardiomyocyte cell cycle and enhances engraftment in the heart.

Manabu Kasamoto, Shunsuke Funakoshi, Takeshi Hatani, Chikako Okubo, Yohei Nishi, Yuta Tsujisaka, Misato Nishikawa, Megumi Narita, Akira Ohta, Takeshi Kimura and 1 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Manabu KasamotoCentre for iPS Cell Research and Application, Kyoto University, Kyoto, Japan; Department of Cardiovascular Medicine, Kyoto University Hospital, Kyoto, Japan.
Shunsuke FunakoshiCentre for iPS Cell Research and Application, Kyoto University, Kyoto, Japan; Takeda-CiRA Joint program (T-CiRA), Fujisawa, Japan. Electronic address: s.funakoshi@cira.kyoto-u.ac.jp.
Takeshi HataniCentre for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Chikako OkuboCentre for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Yohei NishiCentre for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Yuta TsujisakaCentre for iPS Cell Research and Application, Kyoto University, Kyoto, Japan; Department of Cardiovascular Medicine, Kyoto University Hospital, Kyoto, Japan.
Misato NishikawaCentre for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Megumi NaritaCentre for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Akira OhtaCentre for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Takeshi KimuraDepartment of Cardiovascular Medicine, Kyoto University Hospital, Kyoto, Japan.
Yoshinori YoshidaCentre for iPS Cell Research and Application, Kyoto University, Kyoto, Japan; Takeda-CiRA Joint program (T-CiRA), Fujisawa, Japan. Electronic address: yoshinor@cira.kyoto-u.ac.jp.
Kyoto University · JPKyoto University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human induced pluripotent stem cell-derived (hiPSC) cardiomyocytes are a promising source for regenerative therapy. To realize this therapy, however, their engraftment potential after their injection into the host heart should be improved. Here, we established an efficient method to analyze the cell cycle activity of hiPSC cardiomyocytes using a fluorescence ubiquitination-based cell cycle indicator (FUCCI) system. In vitro high-throughput screening using FUCCI identified a retinoic acid receptor (RAR) agonist, Am80, as an effective cell cycle activator in hiPSC cardiomyocytes. The transplantation of hiPSC cardiomyocytes treated with Am80 before the injection significantly enhanced the engraftment in damaged mouse heart for 6 months. Finally, we revealed that the activation of endogenous Wnt pathways through both RARA and RARB underlies the Am80-mediated cell cycle activation. Collectively, this study highlights an efficient method to activate cell cycle in hiPSC cardiomyocytes by Am80 as a means to increase the graft size after cell transplantation into a damaged heart.

Indexed as

Induced Pluripotent Stem CellsMyocytes, CardiacAnimalsBenzoatesCell CycleCell DifferentiationHumansMiceReceptors, Retinoic AcidTetrahydronaphthalenesBenzoatesReceptors, Retinoic AcidtamibaroteneTetrahydronaphthalenesCardiac cell transplantationcardiomyocyte differentiationCell cycleFUCCIhigh throughput screeninghuman induced pluripotent stem cellsretinoic acid

Identifiers

PMID37451261
PMCPMC10444569
OpenAlexW4384207612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.